pioglitazone (CT-L03-301) / Celltrion - LARVOL DELTA

EPIDOTE: A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (clinicaltrials.gov) - P4 | N=133 | Completed | Sponsor: Celltrion Pharm, Inc. | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of pioglitazone versus dapagliflozin as an add-on to metformin and alogliptin combination therapy: the EPIDOTE study. (PubMed, Sci Rep) - "Pioglitazone added to metformin and alogliptin significantly improved glycemic control in patients with type 2 diabetes, and was non-inferior to dapagliflozin. This study suggests that pioglitazone could be an effective and safe option for patients with inadequate glycemic control on metformin and DPP4i."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

CT-L03-301: Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin (clinicaltrials.gov) - P3 | N=582 | Active, not recruiting | Sponsor: Celltrion | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes (clinicaltrials.gov) - P4 | N=120 | Recruiting | Sponsor: Seoul National University Bundang Hospital

New P4 trial • Diabetes • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus